S
StemInov
Drug Discovery company working on a innovative cell based therapy in immunology
About StemInov
StemInov, a clinical stage spin-off from CHRU of Nancy and University of Lorraine, focuses on developing WhartSep, an off-the-shelf allogenic stem cell therapy for inflammatory diseases. The company targets critical care conditions such as sepsis-induced pathologies, ARDS, and septic shock. WhartSep, their primary drug candidate, offers three complementary actions: antibacterial effects, unique immunomodulation, and organ protection. StemInov's business model revolves around advancing WhartSep through clinical trials, leveraging robust preclinical data and safety profiles. The company is preparing for a phase I/II efficacy trial on pneumonia patients at risk of developing septic shock or ARDS. StemInov serves the healthcare sector, particularly hospitals and medical institutions dealing with critical care. Revenue generation is anticipated through successful clinical trials and subsequent commercialization of WhartSep.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Vandœuvre-lès-Nancy, France
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 87.7/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Regenerative Medicine, Sepsis, Spinout, observatoire industrial tech, observatoire healthtech, Critical medical care, Inflammatory Diseases, Drug Development, biotech medtech and e-health, Stem Cells
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2025 | $12M | $47M | Alsace Business Angels · France 2030 · Angels Santé · The ILP Group | ↗ |
| GRANT✓Other financing | Jun 2024 | $5.7M | — | France 2030 | ↗ |
Growth signals
Latest recorded traffic for StemInov is 270 monthly website visits, up 50% over the last three months. StemInov's team grew 100% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Finovam
Bpifrance
France 2030
Series A5 investors entered at this stage
Alsace Business Angels
Angels Santé
The ILP Group
Business Angels Des Grandes Ecoles
Codexial
Other known investors5 additional known investors
HEC Paris
HEC Challenge+
Incubateur Lorrain
University of Lorraine
SATT Sayens
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about StemInov on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See StemInov’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.